New England Journal of Medicine publishes new data for Genentch’s Gazyva showing superiority over standard therapy in people with active lupus nephritis

Your email address will not be published. Required fields are marked *

Comment *

Name *

Email *

Website

Save my name, email, and website in this browser for the next time I comment.